S&P 500   3,116.49 (+0.64%)
DOW   27,977.56 (+0.70%)
QQQ   202.50 (+0.53%)
CGC   15.44 (-2.53%)
BABA   185.38 (+1.41%)
GE   11.50 (+1.86%)
T   39.33 (+0.98%)
ACB   2.83 (-14.00%)
F   8.95 (+1.82%)
PRI   130.88 (+0.52%)
BAC   32.91 (+0.61%)
DIS   144.75 (-1.63%)
S&P 500   3,116.49 (+0.64%)
DOW   27,977.56 (+0.70%)
QQQ   202.50 (+0.53%)
CGC   15.44 (-2.53%)
BABA   185.38 (+1.41%)
GE   11.50 (+1.86%)
T   39.33 (+0.98%)
ACB   2.83 (-14.00%)
F   8.95 (+1.82%)
PRI   130.88 (+0.52%)
BAC   32.91 (+0.61%)
DIS   144.75 (-1.63%)
S&P 500   3,116.49 (+0.64%)
DOW   27,977.56 (+0.70%)
QQQ   202.50 (+0.53%)
CGC   15.44 (-2.53%)
BABA   185.38 (+1.41%)
GE   11.50 (+1.86%)
T   39.33 (+0.98%)
ACB   2.83 (-14.00%)
F   8.95 (+1.82%)
PRI   130.88 (+0.52%)
BAC   32.91 (+0.61%)
DIS   144.75 (-1.63%)
S&P 500   3,116.49 (+0.64%)
DOW   27,977.56 (+0.70%)
QQQ   202.50 (+0.53%)
CGC   15.44 (-2.53%)
BABA   185.38 (+1.41%)
GE   11.50 (+1.86%)
T   39.33 (+0.98%)
ACB   2.83 (-14.00%)
F   8.95 (+1.82%)
PRI   130.88 (+0.52%)
BAC   32.91 (+0.61%)
DIS   144.75 (-1.63%)
Log in

Syros Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:SYRS)

$5.00
-0.20 (-3.85 %)
(As of 11/15/2019 03:08 PM ET)
Today's Range
$4.94
Now: $5.00
$5.15
50-Day Range
$4.99
MA: $7.20
$11.01
52-Week Range
$4.88
Now: $5.00
$11.93
Volume23,098 shs
Average Volume435,780 shs
Market Capitalization$212.20 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYRS
CUSIPN/A
Phone617-744-1340

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.05 million
Book Value$2.34 per share

Profitability

Net Income$-62,280,000.00
Net Margins-3,115.38%

Miscellaneous

Employees76
Market Cap$212.20 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive SYRS News and Ratings via Email

Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.


Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals Inc (NASDAQ:SYRS) issued its earnings results on Tuesday, November, 12th. The company reported ($0.47) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.48) by $0.01. The business had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.43 million. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 86.92%. View Syros Pharmaceuticals' Earnings History.

When is Syros Pharmaceuticals' next earnings date?

Syros Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Syros Pharmaceuticals.

What price target have analysts set for SYRS?

7 brokers have issued twelve-month price targets for Syros Pharmaceuticals' shares. Their forecasts range from $10.00 to $18.00. On average, they anticipate Syros Pharmaceuticals' stock price to reach $14.50 in the next year. This suggests a possible upside of 190.0% from the stock's current price. View Analyst Price Targets for Syros Pharmaceuticals.

What is the consensus analysts' recommendation for Syros Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syros Pharmaceuticals.

Has Syros Pharmaceuticals been receiving favorable news coverage?

News headlines about SYRS stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Syros Pharmaceuticals earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Syros Pharmaceuticals.

Are investors shorting Syros Pharmaceuticals?

Syros Pharmaceuticals saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 2,590,000 shares, an increase of 8.8% from the September 30th total of 2,380,000 shares. Based on an average daily volume of 234,100 shares, the days-to-cover ratio is currently 11.1 days. Approximately 8.6% of the shares of the company are sold short. View Syros Pharmaceuticals' Current Options Chain.

Who are some of Syros Pharmaceuticals' key competitors?

What other stocks do shareholders of Syros Pharmaceuticals own?

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the folowing people:
  • Dr. Nancy A. Simonian, Pres, CEO & Director (Age 58)
  • Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 65)
  • Dr. David A. Roth, Chief Medical Officer (Age 56)
  • Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 57)
  • Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (10.92%), Nikko Asset Management Americas Inc. (10.92%) and Tower Research Capital LLC TRC (0.01%). Company insiders that own Syros Pharmaceuticals stock include Jeremy P Springhorn, Richard A Young, Srinivas Akkaraju and Venture Fund Vii LP Arch. View Institutional Ownership Trends for Syros Pharmaceuticals.

Which institutional investors are buying Syros Pharmaceuticals stock?

SYRS stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc. and Tower Research Capital LLC TRC . Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn and Srinivas Akkaraju. View Insider Buying and Selling for Syros Pharmaceuticals.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $5.00.

How big of a company is Syros Pharmaceuticals?

Syros Pharmaceuticals has a market capitalization of $212.20 million and generates $2.05 million in revenue each year. The company earns $-62,280,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe.View Additional Information About Syros Pharmaceuticals.

What is Syros Pharmaceuticals' official website?

The official website for Syros Pharmaceuticals is http://www.syros.com/.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]


MarketBeat Community Rating for Syros Pharmaceuticals (NASDAQ SYRS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  297 (Vote Outperform)
Underperform Votes:  261 (Vote Underperform)
Total Votes:  558
MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote "Outperform" if you believe SYRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Featured Article: Dividend Aristocrat Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel